WALTHAM, Mass., USA — April 2, 2026
Thermo Fisher Scientific Inc. has announced the global launch of the Gibco™ CTS™ Compleo™ Fill and Finish System, an advanced automated, functionally closed solution designed to streamline cell therapy manufacturing workflows. The system addresses one of the most critical bottlenecks in advanced therapy production—manual formulation and fill processes—by enabling greater consistency, reduced contamination risk, and improved scalability in GMP-compliant manufacturing environments.
Automation Enhances Consistency in Cell Therapy Manufacturing
Cell therapies often rely on patient-derived cells, which introduce variability in cell count, viability, and concentration, making manufacturing highly complex. Traditional manual fill and finish processes require precise handling of fragile cells, increasing the risk of batch variability and contamination.
The CTS Compleo system introduces a fully automated and functionally closed approach, significantly reducing manual intervention while ensuring consistent batch-to-batch performance. This innovation enables manufacturers to maintain high levels of sterility, dose accuracy, and product quality, which are critical for regulatory compliance and successful commercialization of cell and gene therapies.
Closed-System Design Supports GMP Compliance and Scalability
Advertisement
The system’s closed and automated architecture is specifically designed to meet the stringent requirements of Good Manufacturing Practice (GMP) environments, where process control, traceability, and contamination prevention are essential. By minimizing human interaction and integrating digital workflow controls, the Compleo system enhances process reliability and reproducibility, key factors in scaling advanced therapies from clinical development to commercial production.
In addition, the platform offers flexibility through an intuitive protocol builder software, allowing manufacturers to adapt processes across different cell therapy programs. This adaptability is particularly valuable for autologous therapies, where each batch is patient-specific and requires precise customization. Early collaborators have reported improved workflow efficiency and reduced variability, highlighting the system’s potential to accelerate development timelines.
Integrated Bioprocessing Ecosystem Drives Innovation
The CTS Compleo system is part of Thermo Fisher’s broader Gibco™ Cell Therapy Systems (CTS™) portfolio, which includes GMP-grade media, reagents, viral vectors, and software solutions designed to support end-to-end cell and gene therapy manufacturing. This integrated ecosystem enables seamless physical and digital connectivity across the production workflow, supporting efficient process development and scale-up.
Thermo Fisher also provides comprehensive support services, including installation, application development, and global technical support, ensuring smooth adoption and integration into existing manufacturing operations. The system is expected to play a key role in helping biopharmaceutical companies accelerate the delivery of life-saving therapies, while maintaining strict quality and regulatory standards.
Industry Impact and Future Outlook
The launch of the CTS Compleo system reflects a broader industry shift toward automation, closed-system processing, and digital integration in advanced therapy manufacturing. As demand for cell and gene therapies continues to rise, manufacturers are increasingly seeking solutions that improve efficiency, scalability, and compliance without compromising product quality.
By addressing key challenges in the fill and finish stage, Thermo Fisher’s innovation has the potential to significantly reduce production risks and improve time-to-market for advanced therapies. This development underscores the importance of technology-driven transformation in GMP manufacturing, where automation and precision are essential for meeting the evolving needs of the biopharmaceutical industry.
Source: Thermo Fisher Scientific press release
